Oxford BioTherapeutics and Bristol Myers Squibb Forge Oncology Alliance

Oxford BioTherapeutics has announced a selective target collaboration with Bristol Myers Squibb (BMY) aimed at the discovery and development of next-generation T-cell engager therapies specifically designed for solid tumors. The agreement centers on the use of Oxford’s proprietary OGAP-Verify platform, which enables the highly sensitive identification and validation of tumor-selective targets. By utilizing this technology, the partners aim to generate differentiated antibody-based therapies that offer improved attributes for drug development in the oncology space. Under the structural terms of the partnership, Oxford BioTherapeutics will maintain responsibility for the design and delivery of development candidates. Once these candidates are established, Bristol Myers Squibb will assume leadership over all subsequent research, development, and commercialization activities. While the specific financial terms of the agreement were not disclosed, Oxford is set to receive an upfront payment inclusive of research funding. The deal further provides for significant downstream milestone payments and royalties on any products that successfully reach the commercial market. This collaboration represents a continuing trend of strategic growth for Oxford BioTherapeutics. It marks the company's third partnership with a major pharmaceutical entity within the last 12 months, following similar strategic agreements signed with GSK plc and Roche Holding AG in 2025.